Literature DB >> 24200276

Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis.

F Fahimi1, P Tabarsi, F Kobarfard, B D Bozorg, A Goodarzi, F Dastan, N Shahsavari, S Emami, M Habibi, J Salamzadeh.   

Abstract

BACKGROUND: Low concentrations of anti-tuberculosis drugs are related to drug resistance and treatment failure.
OBJECTIVE: To determine the prevalence of low plasma concentrations of anti-tuberculosis drugs.
METHODS: The study was performed among 60 pulmonary tuberculosis (TB) in-patients at a tertiary care university-affiliated hospital in Tehran, Iran. Drug samples were drawn 2 and 6 h post dose for isoniazid (INH), rifampicin (RMP) and pyrazinamide (PZA); related concentrations were determined using high-performance liquid chromatography. Plasma drug concentrations, duration of treatment, age, sex, liver enzyme levels, administered doses and smoking status were evaluated and recorded.
RESULTS: Among 60 patients recruited to the study, the mean (±SD) age was 54.2 (±20.9) years; 39 were female. The median peak plasma concentrations (C(max)) of INH, RMP and PZA were respectively 2.5, 4.0 and 43.6 μg/ml; 81% of the patients had drug plasma concentrations lower than the target ranges for at least one administered drug. Respectively 49.1%, 92.5% and 8.7% of the patients had low concentrations of INH, RMP and PZA.
CONCLUSION: The results indicate that RMP concentrations are below the reference range in most patients, while PZA is within the target range of the standard doses.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24200276     DOI: 10.5588/ijtld.13.0019

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  9 in total

Review 1.  Review of evidence for measuring drug concentrations of first-line antitubercular agents in adults.

Authors:  Kyle John Wilby; Mary H H Ensom; Fawziah Marra
Journal:  Clin Pharmacokinet       Date:  2014-10       Impact factor: 6.447

2.  Factors Influencing Tuberculosis Treatment Outcome in Adult Patients Treated with Thrice-Weekly Regimens in India.

Authors:  Geetha Ramachandran; Hemanth Kumar Agibothu Kupparam; Chandrasekaran Vedhachalam; Kannan Thiruvengadam; Vijayalakshmi Rajagandhi; Azger Dusthackeer; Ramesh Karunaianantham; Lavanya Jayapal; Soumya Swaminathan
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

3.  Rifampicin and isoniazid plasma concentrations in relation to adverse reactions in tuberculosis patients: a retrospective analysis.

Authors:  L Aït Moussa; O El Bouazzi; S Serragui; D Soussi Tanani; A Soulaymani; R Soulaymani
Journal:  Ther Adv Drug Saf       Date:  2016-09-07

4.  Adequacy of Rifampin Absorption after Jejunostomy Tube Administration.

Authors:  Katharine E Stott; Bhagteshwar Singh; Mike B J Beadsworth; Kate Vaudrey; Saye H Khoo; Geraint Davies
Journal:  Pharmacotherapy       Date:  2016-04-06       Impact factor: 4.705

5.  Fast and Simple LC-MS/MS Method for Rifampicin Quantification in Human Plasma.

Authors:  Žane Temova Rakuša; Robert Roškar; Anita Klančar Andrejc; Tina Trdan Lušin; Nataša Faganeli; Iztok Grabnar; Aleš Mrhar; Albin Kristl; Jurij Trontelj
Journal:  Int J Anal Chem       Date:  2019-02-03       Impact factor: 1.885

6.  Determinants of serum concentration of first-line anti-tuberculosis drugs from China.

Authors:  Qian Lei; Hao Wang; Yuan Zhao; Liyun Dang; Changsheng Zhu; Xiaohui Lv; Hui Wang; Jun Zhou
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.817

7.  Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania.

Authors:  Paolo Denti; Kidola Jeremiah; Emmanuel Chigutsa; Daniel Faurholt-Jepsen; George PrayGod; Nyagosya Range; Sandra Castel; Lubbe Wiesner; Christian Munch Hagen; Michael Christiansen; John Changalucha; Helen McIlleron; Henrik Friis; Aase Bengaard Andersen
Journal:  PLoS One       Date:  2015-10-26       Impact factor: 3.240

8.  Simultaneous Determination of Isoniazid, Pyrazinamide and Rifampin in Human Plasma by High-performance Liquid Chromatography and UV Detection.

Authors:  Behnam Dasht Bozorg; Ali Goodarzi; Fanak Fahimi; Payam Tabarsi; Nahid Shahsavari; Farzad Kobarfard; Farzaneh Dastan
Journal:  Iran J Pharm Res       Date:  2019       Impact factor: 1.696

9.  Can diabetes mellitus modify the plasma concentrations of rifampicin in patients under treatment for tuberculosis?

Authors:  Adriana Aparecida Durães Fonseca; Ana Carla Godinho Pinto; Thiago Portal da Paixão; Carlos Augusto Abreu Albério; José Luiz Fernandes Vieira
Journal:  Braz J Infect Dis       Date:  2020-06-11       Impact factor: 3.257

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.